Hints and tips:
...Talecris for $4bn....
...The acquisition by Grifols substantially boosts the Spanish company’s strength in blood products, and follows its purchase of the US blood plasma Talecris for $4bn in 2010....
...Bids open on Friday for Plasma Resources UK, which buys plasma in the US and commercialises its derivatives around the world, including supplying about a third of the total required by the National Health...
...Approval was easy for the $3.4bn cash and stock acquisition of Talecris, the US blood plasma company, by Grifols, its Spanish peer....
...Grifols, which is still part-owned and run by the Grifols founding family in Spain, said the deal would create one of the world’s leading suppliers of plasma protein therapeutics products....
...Talecris Biotherapeutics, a maker of protein therapies, jumped 25.7 per cent to $20.01 after Grifols, Europe’s largest maker of blood plasma products, agreed to buy it for $4bn....
...Notable deals include German drug and chemical group Merck’s $6bn takeover of Millipore, the US laboratory supplies maker, and the decision by Grifols, Europe’s largest maker of blood-plasma products, to...
...An eventual sale of Talecris to one of CSL’s smaller rivals, such as Octopharma or Grifols, could turn it into a stronger competitor against CSL....
International Edition